Libertyville, IL, United States of America

Jianguo Ji

This inventor holds 40 USPTO granted patents and 7 published patent applications, plus 5 CIPO patents and 9 EPO patents, primarily in Pharmaceutical Compositions. Top assignees: Abbott Laboratories Corporation, Abbvie Inc., Abbvie S.a.r.l.. Active years: 2001-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jianguo Ji. Retrieved from https://idiyas.com/inventor/jianguo-ji

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 40 (Patent Applications = 7)

% Patents Active = 37.5

CIPO Patents = 5 (Patent Applications = 17)

EPO Patents = 9 (Patent Applications = 18)

Average Co-Inventor Count = 5.2

ph-index = 11

Forward Citations = 287(Granted Patents)

Location History:

Shanghai, CN (2012 - 2019)
Libertyville, IL (US) (2001 - 2020)

Company Filing History:

24 out of 4,190

Abbott Laboratories Corporation

Hutchison Medipharma Limited

patents

6. 1 out of 2

Hutchinson Medipharma Limited

patents

where one patent can have more than one assignee

Years Active: 2001-2020

Loading Chart...

Areas of Expertise:

Pharmaceutical Compositions

CNS Agents

Syk Inhibitors

Pyrrolopyrimidine Compounds

Azaadamantane Derivatives

Diazabicyclic Agents

Heterocyclic Compounds

Biaryl Derivatives

Tricyclic Derivatives

Nitro Compounds

Neuronal Nicotinic Receptor Ligands

Spirocyclic Derivatives

40 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10647717 - N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use (2020-05-12),

2. 10369153 - Pyrrolopyrimidine compounds and uses thereof (2019-08-06),

3. 10259810 - N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use (2019-04-16),

4. 10130622 - Compounds for treatment of cystic fibrosis (2018-11-20),

5. 10111875 - Pyrrolopyrimidine compounds and uses thereof (2018-10-30),

6. 10052330 - Substituted pyrido[3,4-b]pyrazines as Syk inhibitors (2018-08-21),

7. 9890158 - N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use (2018-02-13),

8. 9796711 - [object Object] (2017-10-24),

9. 9434726 - Substituted pyrido[3,4-b]pyrazines as Syk inhibitors (2016-09-06),

10. 9346810 - Pyrrolopyrimidine compounds and uses thereof (2016-05-24),

11. 9186407 - Pharmaceutical compositions and their methods of use (2015-11-17),

12. 9040568 - Pharmaceutical compositions for the treatment of pain (2015-05-26),

13. 8987453 - Azaadamantane derivatives and methods of use (2015-03-24),

14. 8853241 - Biaryl substituted azabicyclic alkane derivatives (2014-10-07),

15. 8486979 - 1,2,4 oxadiazole compounds and methods of use thereof (2013-07-16),

Title: Innovations and Contributions of Jianguo Ji

Introduction

Jianguo Ji, based in Libertyville, IL, is a prolific inventor recognized for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 40 patents, Ji’s innovations aim to address critical health issues through novel compounds and therapeutic methods.

Latest Patents

Jianguo Ji has recently been granted patents for groundbreaking compounds including N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides, which are designed to target diseases mediated by CFTR, such as cystic fibrosis and chronic obstructive lung disease. This invention encompasses pharmaceutical compositions that comprise compounds of formula (I). Furthermore, his work on pyrrolopyrimidine compounds has led to methods that inhibit JAK kinases, offering potential treatments for inflammatory diseases and cancer.

Career Highlights

Throughout his career, Jianguo Ji has been associated with prominent companies such as Abbott Laboratories Corporation and AbbVie Inc. His efforts at these institutions have been pivotal in advancing therapeutic strategies that leverage his patent innovations.

Collaborations

Jianguo has worked alongside noted colleagues like Tao Li and Kevin B. Sippy, fostering collaborative efforts that enhance the research and development of new pharmaceutical treatments.

Conclusion

Jianguo Ji's innovative spirit and dedication to advancing medical science are evident in his extensive patent portfolio. His contributions not only pave the way for new therapies but also exemplify the impact of collaboration in the field of pharmaceutical innovation.

Profile summary based on public USPTO records.